HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide

Multiple myeloma (MM) is a hematological malignancy of plasma cells in the bone marrow. Despite multiple treatment options, MM is inevitably associated with drug resistance and poor outcomes. Histone deacetylase inhibitors (HDACi's) are promising novel chemotherapeutics undergoing evaluation in...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Oncotarget
Κύριοι συγγραφείς: Canella, Alessandro, Nieves, Hector Cordero, Sborov, Douglas W., Cascione, Luciano, Radomska, Hanna S., Smith, Emily, Stiff, Andrew, Consiglio, Jessica, Caserta, Enrico, Rizzotto, Lara, Zanesi, Nicola, Stefano, Volinia, Kaur, Balveen, Mo, Xiaokui, Byrd, John C., Efebera, Yvonne A., Hofmeister, Craig C., Pichiorri, Flavia
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Impact Journals LLC 2015
Θέματα:
Research Paper
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741593/
https://ncbi.nlm.nih.gov/pubmed/26429859
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια